ECTRIMS 2024: Tolebrutinib may target smoldering inflammation
Sep 23, 2024 · Sanofi’s tolebrutinib significantly delayed disability progression, by 31%, and increased the rates of disability improvement compared with a placebo in people with nonrelapsing secondary...
Sanofi lifts lid on data behind tolebrutinib’s mixed MS studies
Sep 20, 2024 · Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate tolebrutinib, linking the BTK inhibitor to a 31% delay in time to onset of...
Press Room - Sanofi US News
Sep 20, 2024 · Tolebrutinib is an investigational, oral, brain-penetrant, and bioactive Bruton’s tyrosine kinase (BTK) inhibitor that achieves CSF concentrations predicted to modulate B lymphocytes and disease-associated microglia.
Feb 23, 2023 · Tolebrutinib is an investigational brain-penetrant and bioactive Bruton’s tyrosine kinase (BTK) inhibitor that achieves CSF concentrations predicted to modulate B lymphocytes and microglial cells.
Tolebrutinib Long-term Data Continue to Show the BTK Inhibitor …
Apr 25, 2023 · Tolebrutinib is a Bruton tyrosine kinase (BTK) inhibitor that is being investigated for use in patients who have relapsing multiple sclerosis (MS); investigators presented safety data from a...
Multiple sclerosis pill succeeds in key trial, Sanofi says - STAT
Sep 2, 2024 · Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a Phase 3 study, potentially clearing the way for regulatory approval, although in two other studies ...
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK ...
Tolebrutinib was well tolerated, with no adverse events leading to treatment withdrawal, and our results suggest an acceptable safety and tolerability profile for tolebrutinib across all doses. Imaging data showed a clear and meaningful effect of tolebrutinib on acute inflammation based on the formation of new gadolinium-enhancing lesions.
ECTRIMS 2023: Tolebrutinib show benefits for up to 3 years
Oct 16, 2023 · Treatment with tolebrutinib for up to nearly three years was tied to low relapse rates, stable disability, and few new brain lesions among people with relapsing forms of multiple sclerosis (MS),...
AAN 2023: Tolebrutinib safely lowering relapse rates at 2.5 years...
Apr 26, 2023 · Over 2 years of treatment with tolebrutinib was safe and kept relapse rates low for multiple sclerosis patients in a Phase 2 trial extension.
Bruton tyrosine kinase inhibitors for multiple sclerosis
Apr 13, 2023 · Tolebrutinib shows increased CNS penetrance, higher potency and faster reaction rates of BTK inhibition compared with both evobrutinib and fenebrutinib 178.
- Some results have been removed